• Grail flagged new data from the NHS-Galleri trial and PATHFINDER 2 for release at EDCC on Oct. 6-8, 2026.
• Additional results are scheduled for ESMO Congress 2026 on Oct. 23-27, 2026.
• Readouts are set to support the Galleri multi-cancer test’s performance across diverse populations, including racial and ethnic groups.
• Planned presentations also address real-world diagnostic workups, including safety, efficiency, earlier detection potential, and fewer emergency cancer diagnoses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grail Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610051601PR_NEWS_USPR_____LA64117) on October 05, 2026, and is solely responsible for the information contained therein.